Clinical Trials Browser

Completed × Carcinoma, Non-Small-Cell Lung × trametinib × Clear all

NCT04452877 2026-01-13

A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

Phase 2 Completed

40 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT03299088 2025-05-21

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

Phase 1 Completed

15 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT04967079 2024-04-23

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT01336634 2022-04-04

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Phase 2 Completed

177 enrolled 19 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase 1 Completed

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT01362296 2014-07-11

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Phase 2 Completed

134 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung